Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.
In this report the mechanism of therapeutic activity of OK-432 for the treatment of peritoneal carcinomatosis was investigated by correlating effector-cell augmentation with therapeutic activity in rats bearing MADB-106 carcinomatosis. Tumor cells were injected i.p. and the treatment with OK-432 was initiated 5 days later with 0.5, 1, 5 or 10 KE/animal of OK-432 injected i.p. semiweekly. Significant therapeutic activity was observed at all doses examined with greater prolongation of survival noted at the higher doses of OK-432. Animals treated with 0.5 KE/animal had a prolongation of the median survival time from 14 days for saline-treated animals to 17 days for the OK-432 treated animals (P less than 0.0008), while animals treated with higher doses had much longer periods of survival, some animals being tumor-free at 185 days. In the same studies, natural killer (NK) cell, lymphokine-activated killer cell, cytotoxic T lymphocyte, and macrophage tumoricidal/cytostatic activities were measured 7 days and 14 days following tumor injection (2 days and 9 days after initiation of immunotherapy). OK-432 had immunostimulatory activity in most of the assays of immune function examined and this correlated with host survival, including augmentation of peritoneal and peripheral blood cytotoxic T lymphocyte activity on day 14, peritoneal and alveolar macrophage activity on day 7 and day 14, as well as natural killer cell activity on day 14. These results suggest that the therapeutic doses are also immunomodulatory doses for the effector cells mentioned above. We suggest, therefore, that immunological monitoring may help to optimize treatment protocols for the treatment of peritoneal and perhaps pleural effusions with OK-432.
Fukui
H
H
Chugai Pharmaceutical Company, Shizuoka, Japan.
Reynolds
C W
CW
Lenz
B
B
Schneider
M
M
Talmadge
J E
JE
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001688:Biological Products / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D002460:Cell Line; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D007694:Killer Cells, Natural / Q000187:drug effects; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D009368:Neoplasm Transplantation; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010844:Picibanil / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects
D000276:Adjuvants, Immunologic; D001688:Biological Products; D010844:Picibanil